Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Developmental toxicity / teratogenicity

Currently viewing:

Administrative data

Endpoint:
developmental toxicity
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Study period:
August 2011 - June 2012
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2012
Report date:
2012

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
other: OECD 422
GLP compliance:
yes (incl. QA statement)
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
3,4,5,6-tetrachloro-N-[2-(4,5,6,7-tetrachloro-2,3-dihydro-1,3-dioxo-1H-inden-2-yl)-8-quinolyl]phthalimide
EC Number:
250-063-5
EC Name:
3,4,5,6-tetrachloro-N-[2-(4,5,6,7-tetrachloro-2,3-dihydro-1,3-dioxo-1H-inden-2-yl)-8-quinolyl]phthalimide
Cas Number:
30125-47-4
Molecular formula:
C26H6Cl8N2O4
IUPAC Name:
4,5,6,7-tetrachloro-2-[2-(4,5,6,7-tetrachloro-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)quinolin-8-yl]-1H-isoindole-1,3(2H)-dione
Test material form:
solid: nanoform
Details on test material:
solid yellow

Test animals

Species:
rat
Strain:
Wistar
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Charles River Laboratories, Research Models and ServiceGmbH, Sulzfeld, Germany
- Age at study initiation: 10-11 weeks
- Weight at study initiation:
- Fasting period before study: no
- Housing: individually, following exceptions: During overnight matings, male and female mating partners were housed together. Pregnant animals and their litters were housed together until PND 4 (end of lactation).
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 7d

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12

IN-LIFE DATES: From: August 9th, 2011 To:October 6th, 2011

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
water
Details on exposure:
PREPARATION OF DOSING SOLUTIONS:

DIET PREPARATION
- Rate of preparation of diet (frequency): weekly
- Mixing appropriate amounts with (Type of food): water
- Storage temperature of food: RT

- applied as a suspension
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
- according GLP
- stability of the test substance in drinking water for a period of 7 days at room temperature was proven before the start of the study
- method stability of test item in drinking water: UV/VIS spectroscopy
Details on mating procedure:
- Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1:1
- Length of cohabitation: overnight for maximum 2 weeks
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy
Duration of treatment / exposure:
The duration of treatment covered a 2-week premating and a mating period in both sexes, approximately 1 week post-mating in males,
and the entire gestation period as well as 4 days of lactation and 2 weeks thereafter in females.
Frequency of treatment:
daily
Doses / concentrationsopen allclose all
Dose / conc.:
100 mg/kg bw/day (actual dose received)
Dose / conc.:
300 mg/kg bw/day (actual dose received)
Dose / conc.:
1 000 mg/kg bw/day (actual dose received)
No. of animals per sex per dose:
10
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale: range finder test 300 and 1000 mg/kg bw, no effects up to 1000 mg/kg bw
- Rationale for animal assignment (if not random): Randomization

Examinations

Maternal examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily

BODY WEIGHT: Yes
- Time schedule for examinations: before the start of the administration period in order to randomize the animals. During the administration period body weight was determined on study day 0 (start of the administration period) and thereafter once a week at the same time of the day (in the morning).

FOOD CONSUMPTION
- weekly
- Food consumption was not determined during the mating period (male and female F0 animals).
- Food consumption of the F0 females with evidence of sperm was determined on GD 0, 7, 14 and 20.
- Food consumption of F0 females, which gave birth to a litter, was determined for PND 4

OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: in the course of FOB
- Dose groups that were examined: all

HAEMATOLOGY: Yes
- Time schedule for collection of blood: end of administration period
- Anaesthetic used for blood collection: Yes, anaesthetized using isoflurane (Isoba®, Essex GmbH, Munich, Germany)
- Animals fasted: Yes
- How many animals: 5/sex/dose

CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: end of administration period
- Animals fasted: Yes
- How many animals: 5/sex/dose

URINALYSIS: Yes
- Time schedule for collection of urine: males: after mating, females: 1 day before end of administration period
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes

NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: male: postnatal day 0, female: 10d after gestation
- Dose groups that were examined: all
- Battery of functions tested: sensory activity / grip strength / motor activity
Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes / No / No data
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: No
- Number of implantations: Yes
- Number of early resorptions: No
- Number of late resorptions: No
Fetal examinations:
- External examinations: Yes, all pubs
- Soft tissue examinations: necropsy observations macroscopically
- Skeletal examinations: No
- Head examinations: No
- Sex ratio
- Pup body weight data
- Pup clinical observations
Statistics:
Blood parameters:
For parameters with bidirectional changes:
Non-parametric one-way analysis using KRUSKAL-WALLIS test. If the resulting p-value was equal or less than 0.05, a pairwise comparison of each dose
group with the control group was performed using WILCOXON-test (twosided) for the hypothesis of equal medians
For parameters with unidirectional changes:
Pairwise comparison of each dose group with the control group using the WILCOXON-test (one-sided) for the hypothesis of equal medians

Urinalysis parameters: WILCOXON-test (one-sided)

Food consumption: DUNNETT-test (twosided)

fertility indices: FISHER'S EXACT test

Proportions of affected pups per litter with necropsy observations: WILCOXON-test

Weight parameters: KRUSKAL-WALLIS test
Indices:
Pup number and status at delivery
Pup viability/mortality
Sex ratio
Pup body weight data

Results and discussion

Results: maternal animals

General toxicity (maternal animals)

Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
- All female animals of test group 3 (1000 mg/kg bw/d) showed yellowish discolored feces at the end of the study.
- In one female animal of test group 1 (100 mg/kg bw/d) abdominal distension was observed on study days 49 and 50.
Mortality:
mortality observed, non-treatment-related
Description (incidence):
- One female of the low dose group (100 mg/kg bw/d) was sacrificed moribund on study day 50 (the animal was not pregnant). It revealed dilation of uterus and cervix with a cloudy fluid content. This was histopathologically diagnosed as a diffuse inflammation with dilation and was regarded to be the cause for the infertility of this mating pair and also the reason for sacrificing this animal. It was a single case and not regarded to be treatment-related but spontaneous in origin.
Body weight and weight changes:
no effects observed
Food consumption and compound intake (if feeding study):
effects observed, non-treatment-related
Description (incidence and severity):
- During the first premating week as well as in the first gestation week the food consumption in female animals of test group 3 (1000 mg/kg bw/d) was significantly increased. These findings were assessed as spontaneous in nature and not test substance-related.
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
no effects observed
Haematological findings:
no effects observed
Clinical biochemistry findings:
no effects observed
Urinalysis findings:
no effects observed
Behaviour (functional findings):
effects observed, non-treatment-related
Description (incidence and severity):
- Functional observational battery: Deviations from "zero values" were obtained in several rats. However, as most findings were equally distributed between test substance-treated groups and controls, were without a dose-response
relationship or occurred in single rats only, these observations were considered to have been incidental.
- Motor activity measurement: Deviations to the control were only noted in test group 1 (100 mg/kg bw/d), i.e. increased value in interval 6 in female animals. As no significant deviations were noted with regard to the overall motor activity and no dose-response relationship was observed, the findings were assessed as being incidental.
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
effects observed, non-treatment-related
Description (incidence and severity):
- The weight increase in absolute and relative spleen weight in females of test group 2 (300 mg/kg bw/d) was regarded to be incidental due to a missing dose-response relationship and missing histopathologic findings in test group 3 (1000 mg/kg bw/d).
Gross pathological findings:
effects observed, treatment-related
Description (incidence and severity):
- 7 females of test group 3 (1000 mg/kg bw/d) revealed a yellow discoloration of the glandular stomach contents. 3 females of test group 3 (1000 mg/kg bw/d) showed the same discoloration of the contents of the jejunum.
- One female animal of test group 1 (100 mg/kg bw/d) revealed a yellow discoloration of the lung (regarded to be test substance that was aspired subsequently to the gavage procedure or due to a gavage error into the trachea) and the mediastinal lymph nodes (regarded to be the physiologic clearing route of the lung).
These discolorations were caused by the test substance but were not regarded to be a treatmentrelated adverse finding.
Neuropathological findings:
no effects observed
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Description (incidence and severity):
- 2 females of test group 3 (1000 mg/kg bw/d) revealed histopathological yellow crystalline particles within the alveoli, often close to or within macrophages, rarely inside multinucleated giant cells. The same finding was also observed for the female animal of test group 1 that revealed the macropscopic finding “discoloration” in the lung. These yellow particles were regarded to be test substance that was aspired subsequently to the gavage procedure. Therefore, these discolorations in lung and mediastinal lymph node were caused by the test substance but were not regarded to be a treatment-related adverse finding.
Histopathological findings: neoplastic:
no effects observed
Other effects:
no effects observed

Maternal developmental toxicity

Number of abortions:
not examined
Pre- and post-implantation loss:
effects observed, non-treatment-related
Description (incidence and severity):
The mean postimplantation loss was highest in test group 2 (300 mg/kg bw/d), i.e. 28.6% compared to the control group (13.8%). As no dose-response relationship was observed, the finding was assessed as not being related to treatment.
Total litter losses by resorption:
not examined
Early or late resorptions:
not examined
Dead fetuses:
not examined
Changes in pregnancy duration:
no effects observed
Changes in number of pregnant:
effects observed, non-treatment-related
Description (incidence and severity):
1 female of the control group, 2 females of test group 1 (100 mg/kg bw/d), 3 females of test group 2 (300 mg/kg bw/d) and 1 female of test group 3 (1000 mg/kg bw/d) were either sperm-negative or did not become pregnant. These findings were assessed to be incidental and not related to treatment as no dose-response relationship was observed.
Other effects:
no effects observed
Details on maternal toxic effects:
Maternal toxic effects:no effects

Effect levels (maternal animals)

open allclose all
Dose descriptor:
NOAEL
Effect level:
1 000 mg/kg bw/day
Basis for effect level:
other: maternal toxicity
Dose descriptor:
NOAEL
Effect level:
1 000 mg/kg bw/day
Basis for effect level:
other: developmental toxicity

Maternal abnormalities

Abnormalities:
no effects observed

Results (fetuses)

Fetal body weight changes:
effects observed, non-treatment-related
Description (incidence and severity):
(instead of fetal body weight changes, the body weight of the pups was assessed)

Mean pup body weights were significantly lower on PND1 in test groups 2 (300 mg/kg bw/d) and 3 (1000 mg/kg bw/d).
One female runt was seen in test group 2 (300 mg/kg bw/d) and 2 male and 3 female runts in test group 3 (1000 mg/kg bw/d).
These values were within the range of the biological variation inherent in the strain of rats used for this study.
Reduction in number of live offspring:
effects observed, non-treatment-related
Description (incidence and severity):
one stillborn pup in test group 1 (100 mg/kg bw/d)
Changes in sex ratio:
no effects observed
Changes in litter size and weights:
no effects observed
Changes in postnatal survival:
effects observed, non-treatment-related
Description (incidence and severity):
The viability index as indicator for pup mortality between PND 0 and 4 was 99% for test groups 1 and 3 (100 and 1000 mg/kg bw/d; 1 pup of 1 female in group 1 and 3 was found dead).
These findings were assessed to be incidental and not related to treatment.
External malformations:
no effects observed
Skeletal malformations:
no effects observed
Visceral malformations:
effects observed, non-treatment-related
Description (incidence and severity):
A situs inversus of the heart was observed in one pup of test group 3 (1000 mg/kg bw/d). The finding was assessed as being spontaneous in nature and without biological relevance.
Other effects:
no effects observed
Details on embryotoxic / teratogenic effects:
Embryotoxic / teratogenic effects:no effects

Effect levels (fetuses)

Dose descriptor:
NOAEL
Effect level:
1 000 mg/kg bw/day (actual dose received)
Sex:
male/female
Basis for effect level:
other: no adverse effects observed up to and including the limit dose

Fetal abnormalities

Abnormalities:
not examined

Overall developmental toxicity

Developmental effects observed:
no

Any other information on results incl. tables

Table 1: Summary of female reproduction and delivery data

 

ORAL ADMINISTRATION(GAVAGE) - F0 FEMALES (Fl LITTER)

SUMMARY OF FEMALE REPRODUCTION AND DELIVERY DATA

 

 

 

 

TEST GROUP 0

0 MG/KG BW/D

TEST GROUP 1

100 MG/KG BW/D

TEST GROUP 2

300 MG/KG BW/D

TEST GROUP 3

1000 MG/KG BW/D

 

Females on Study

N

10

10

10

10

 

Females Mated

N

10Fi

10

8

10

 

Female Mating Index

%

100

100

80

100

 

Mating days until day 0 pc

MEAN

3.8D

1.9

2.3

4.2

 

 

S.D.

3.39

1.66

1.49

3.33

 

 

N

10

10

8

10

 

days 1 to4

N

9

9

8

9

 

 

%

90

90

100

90

 

days 5 to8

N

0

1

0

0

 

 

%

0.0

10

0.0

0.0

 

days 9 to 14

N

1

0

0

1

 

 

%

10

0.0

0.0

10

 

days 15 to 21

N

0

0

0

0

 

 

%

0.0

0.0

0.0

0.0

 

Females Pregnant

N

9Fi

8

7

9

 

Female Fertility Index

%

90

80

88

90

 

Duration of Gestation (Days)

MEAN

22.1D

22.0

21.8

21.9

 

 

S.D.

0.35

0.00

0.45

0.33

 

 

Implantation sites

 

TOTAL

 

101

 

90

 

71

 

123

 

 

MEAN

11.2 D

11.3

10.1

13.7

 

 

S.D.

3.49

2.60

6.15

2.06

 

 

N

9

8

7

9

 

Postimplantation Loss

TOTAL

5

1

3

2

 

 

MEAN

0.6 D

0.1

0.4

0.2

 

 

S.D.

0.88

0.35

0.79

0.44

 

 

N

9

8

7

9

 

% Postimplantation Loss

MEAN

13.8 D

1.6

28.6

1.4

 

 

S.D.

32.82

4.42

48.80

2.83

 

 

TEST GROUP 0

0 MG/KGBW/D

TEST GROUP 1

100 MG/KG BW/D

TEST GROUP 2

300 MG/KG BW/D

TEST GROUP 3

1000 MG/KG BW/D

Females with Liveborn

N

8Fi

8

5

9

Gestation Index

%

89

100

71

100

with Stillborn Pups

N

0Fi

1

0

0

 

%

0.0

13

0.0

0.0

with all Stillborn

N

0Fi

0

0

0

 

%

0.0

0.0

0.0

0.0

Pups Delivered

MEAN

12.0 D

11.1

13.6

13.4

 

S.D.

0.93

2.80

2.07

1.81

 

TOTAL

96

89

68

121

Liveborn

N

96Fi

88

68

121

Live Birth Index

%

100

99

100

100

Stillborn

N

0Fi

1

0

0

 

%

0.0

1.1

0.0

0.0

Table 2: Summary of litter data

 

TEST GROUP0

0 MG/KGBW/D

TEST GROUP 1

100 MG/KG BW/D

TEST GROUP 2

300 MG/KG BW/D

TEST GROUP 3

1000 MG/KG BW/D

(Total Number of) Litters

N

8

8

5

9

Litters with LivebornPups

N

8Fi

8

5

9

 

%

100

100

100

100

Litters with StillbornPups

N

0Fi

1

0

0

 

%

0.0

13

0.0

0.0

Litters with all Stillborn Pups

N

0Fi

0

0

0

 

%

0.0

0.0

0.0

0.0

Pups Delivered

TOTAL

96

89

68

121

 

MEAN

12.0 D

11.1

13.6

13.4

 

S.D.

0.93

2.80

2.07

1.81

Pups Liveborn

N

96Fi

88

68

121

 

%

100

99

100

100

Pups Stillborn

N

0Fi

1

0

0

 

%

0.0

1.1

0.0

0.0

Pups Died

N

0Fi

1

0

1

 

%

0.0

1.1

0.0

0.8

Pups Sacrificed Moribund

N

0Fi

0

0

0

 

%

0.0

0.0

0.0

0.0

Pups Cannibalized

N

0Fi

0

0

0

 

%

0.0

0.0

0.0

0.0

Pups Accidental Death

N

0

0

0

0

 

%

0.0

0.0

0.0

0.0

Pups Sacrificed, Maternal Death

N

0

0

0

0

 

%

0.0

0.0

0.0

0.0

 

TEST GROUP0

0 MG/KGBW/D

TEST GROUP 1

100 MG/KG BW/D

TEST GROUP 2

300 MG/KG BW/D

TEST GROUP 3

1000 MG/KG BW/D

Pups dead day 0

N

0

0

0

0

 

%

0.0

0.0

0.0

0.0

days 1 to 4

N

0

1

0

1

 

%

0.0

1.1

0.0

0.8

Pups Surviving days O to 4

N

96Fi

87

68

120

Viability Index

%

100

99

100

99

Table 3: Summary of necropsy observations

 

TEST GROUP0

0 MG/KGBW/D

TEST GROUP 1

100 MG/KG BW/D

TEST GROUP 2

300 MG/KG BW/D

TEST GROUP 3

1000 MG/KG BW/D

Litters Evaluated

N

8

8

5

9

Pups Evaluated

N

95

89

68

120

Live

N

95

88

68

120

Stillborn

N

0

1

0

0

HEART, SITUS INVERSUS

 

 

 

 

 

Pup Incidence

N

0

0

0

1

 

%

0.0

0.0

0.0

0.8

Litter Incidence

N

0Fi

0

0

1

 

%

0.0

0.0

0.0

11

Affected Pups/Litter

MEAN%

0.0Wi

0.0

0.0

0.7

 

S.D.

0.00

0.00

0.00

1.96

TOTAL PUP NECROPSY OBSERVATIONS

 

 

 

 

 

Pup Incidence

N

0

0

0

1

 

%

0.0

0.0

0.0

0.8

Litter Incidence

N

0Fi

0

0

1

 

%

0.0

0.0

0.0

11

Affected Pups/Litter

MEAN%

0.0Wi

0.0

0.0

0.7

 

S.D.

0.00

0.00

0.00

1.96

Statistics: D=Dunnett-test (two-sided); Fi =Fisher's exact test (one-sided); Wi=Wilcoxon-test (one-sided)

* : p<=0.05 ** : p<=0.01

Applicant's summary and conclusion

Conclusions:
Under the conditions of this Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test the oral administration by gavage to male and female Wistar rats did not reveal signs of toxicity. The NOAEL for reproductive performance, fertility and developmental toxicity was set to 1000 mg/kg bw/d in male and female Wistar rats.
Executive summary:

A study according to OECD Guideline 422 was performed.

Under the conditions of this Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test the oral administration by gavage to male and female Wistar rats did not reveal signs of toxicity. The NOAEL for reproductive performance, fertility and developmental toxicity was set to 1000 mg/kg bw/d in male and female Wistar rats.